Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study

Table 2 Subanalysis of treatment efficacy in patients treated with MMF

	ARR	p	EDSS	P	On-MMF, Patients, %
	Median (Range)	p	Median (Range)	P	Relapse free	Improved ARR	Improved or Stabilized EDSS
Total patients (n = 86)
Pre-MMF treatment	1.4(0.1–11)	< 0.0001	3(0–8.5)	0.006	64	87	87
on-MMF treatment	0(0–2.8)	< 0.0001	2.5(0–8.5)	0.006	64	87	87
Patients with high dose MMF treatment (n = 52)
Pre-MMF treatment	1.5(0.1–11)	< 0.0001	3(0–8.5)	0.511	81	92	89
on-MMF treatment	0(0–2.8)	< 0.0001	2.5(0–8.5)	0.511	81	92	89
Patients with moderate dose MMF treatment (n = 23)
Pre-MMF treatment	1.4(0.2–6)	0.0003	3(0–8.5)	0.071	52	78	83
on-MMF treatment	0(0–2.2)	0.0003	2(0–6.5)	0.071	52	78	83
Patients with low dose MMF treatment (n = 11)
Pre-MMF treatment	1.2(0.5–6)	0.0078	4(0–8.5)	0.438	9	82	91
on-MMF treatment	0.5(0–1.0)	0.0078	4(0–8.5)	0.438	9	82	91

ISSN: 1471-2377